Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

538
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
538
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

520
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
520
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

400
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
400
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

965
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
965
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognosis Prediction and Shared Decision Making for Personalised Anticoagulant Therapy after Unprovoked Venous Thromboembolism: The MORPHEUS project.

Thrombosis and haemostasis·2026
Same author

Prognosis of Recurrent Venous Thromboembolism During Extended Apixaban Therapy for Cancer-Associated Thrombosis: Insights From the API-CAT Randomized Trial.

Circulation·2026
Same author

YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer: A Randomized Clinical Trial.

JAMA·2026
Same author

Impact of ABO blood groups on residual pulmonary vascular obstruction in patients with unprovoked pulmonary embolism.

Blood vessels, thrombosis & hemostasis·2026
Same author

Prescribing patterns and clinician preferences for direct oral anticoagulant use in unusual site venous thromboembolism: a cross-sectional analysis from the Direct oral anticoagulants in Unusual Site venous Thromboembolism (DUST) study.

Research and practice in thrombosis and haemostasis·2026
Same author

Impact of adherence to elastic compression stockings on efficacy to prevent postthrombotic syndrome: a prespecified analysis of the Compression Elastique Evaluation du Syndrome post Thrombotique study.

Research and practice in thrombosis and haemostasis·2026

Related Experiment Video

Updated: Feb 25, 2026

A Porcine Model of Acute Autologous Pulmonary Embolism
07:44

A Porcine Model of Acute Autologous Pulmonary Embolism

Published on: September 6, 2024

890

[Anticoagulation after an acute pulmonary embolism].

Raphael Le Mao1, Cécile Tromeur1, Francis Couturaud1

  • 1CHU La-Cavale-Blanche, département de médecine interne et pneumologie, EA 3878 (GETBO), IBSAM, CIC Inserm 1412, boulevard Tanguy-Prigent, 29609 Brest cedex, France.

Presse Medicale (Paris, France : 1983)
|July 31, 2017
PubMed
Summary

Determining optimal anticoagulation duration for pulmonary embolism (PE) involves balancing recurrence risk and bleeding. For provoked PE, 6 months is often sufficient; for unprovoked PE, treatment duration requires careful individual risk assessment.

More Related Videos

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

644
Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots
08:02

Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots

Published on: October 25, 2024

890

Related Experiment Videos

Last Updated: Feb 25, 2026

A Porcine Model of Acute Autologous Pulmonary Embolism
07:44

A Porcine Model of Acute Autologous Pulmonary Embolism

Published on: September 6, 2024

890
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

644
Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots
08:02

Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots

Published on: October 25, 2024

890

Area of Science:

  • Cardiology
  • Hematology
  • Internal Medicine

Background:

  • Acute pulmonary embolism (PE) necessitates careful consideration of anticoagulation duration.
  • Balancing the risk of recurrent venous thromboembolism against bleeding complications is crucial.

Purpose of the Study:

  • To analyze the benefit-risk balance for determining optimal anticoagulation duration after acute pulmonary embolism.
  • To evaluate clinical, biochemical, and morphological variables for predicting recurrence risk.

Main Methods:

  • Analysis of clinical variables for predicting recurrent venous thromboembolism.
  • Assessment of bleeding risk during anticoagulant therapy.
  • Review of current evidence on anticoagulation durations (3 months, 6 months, 1-2 years, indefinite).

Main Results:

  • A minimum anticoagulation duration of 3 months is established for PE.
  • For PE provoked by transient risk factors, anticoagulation beyond 6 months is generally not justified.
  • For unprovoked PE, extending anticoagulation beyond 6 months does not consistently reduce long-term recurrence risk, suggesting 3-6 months or indefinite treatment based on individual risk.

Conclusions:

  • Optimal anticoagulation duration for PE depends on whether the event was provoked or unprovoked.
  • Identifying low-risk patients with unprovoked PE is key to avoiding unnecessary indefinite anticoagulation.
  • Future research, including trials on direct oral anticoagulants, is needed to refine clinical practice guidelines.